.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
QuintilesIMS
Citi
Cantor Fitzgerald
Johnson and Johnson
Farmers Insurance
Harvard Business School
AstraZeneca
UBS

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206947

« Back to Dashboard
NDA 206947 describes LENVIMA, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the LENVIMA profile page.

The generic ingredient in LENVIMA is lenvatinib mesylate. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.

Summary for NDA: 206947

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3

Pharmacology for NDA: 206947

Suppliers and Packaging for NDA: 206947

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-708 62856-708-30 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-708-30) > 10 CAPSULE in 1 BLISTER PACK (62856-708-05)
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-710 62856-710-30 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-710-30) > 5 CAPSULE in 1 BLISTER PACK (62856-710-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4MG BASE
Approval Date:Feb 13, 2015TE:RLD:Yes
Patent:► SubscribePatent Expiration:Oct 19, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Sep 19, 2026Product Flag?YSubstance Flag?YDelist Request?
Regulatory Exclusivity Expiration:May 13, 2019
Regulatory Exclusivity Use:EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Novartis
Cerilliant
McKinsey
Argus Health
Merck
Deloitte
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot